Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS)
CNY29.72
+2.07 (+7.49%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 484 Parrot Avenue
Wuhan, CN
Wuhan, CN
CEO
Jun Wang
Website
whjm.com
IPO
2004-04-19
ISIN CNE000001HB7
Description
Jianmin Pharmaceutical Group Co.,Ltd. operates within China, focusing on the production and distribution of traditional Chinese medicines. The company's product line features pediatric pharmaceuticals, prominently sold under its Jianmin and Longmu brand names. In addition to these offerings, Jianmin provides a range of over-the-counter (OTC) drugs, various medical and health products, and consultation services. The firm's main corporate offices are located in Wuhan, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY29.72
+2.07 (+7.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.15
Float Shares
152.29M
Free Float %
99.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.03% | -1.90% | -4.01% | -7.40% | -17.92% | -9.38% | -23.55% | -59.42% | -32.16% | +21.83% | +269.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
29.72
DCF (Unlevered)
109.67
+269.0%
DCF (Levered)
71.85
+141.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.22
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-4.4% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-1.3% Q1'26: -21.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.7% Q1'26: +14.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.9% Q1'26: +8.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.2% ★ Q1'26: +14.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.97× ★ Q1'26: 0.80× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.28B
est: 2.17B (+5.3%)
|
2.36B
est: 2.36B (0.0%)
|
2.71B
est: 2.90B (-6.5%)
|
3.27B
est.
|
2.16B
est: 3.44B (-37.2%)
|
3.30B
est: 3.35B (-1.6%)
|
2.46B
est: 3.35B (-26.8%)
|
3.64B
est: 3.85B (-5.4%)
|
4.21B
est: 4.13B (+2.1%)
|
3.50B
est: 5.09B (-31.2%)
|
3.35B
est: 3.83B (-12.5%)
|
4.19B
4.19B – 4.19B
+9.4% YoY
|
4.56B
4.56B – 4.56B
+8.8% YoY
|
| EBITDA |
117.74M
est: 221.23M (-46.8%)
|
91.50M
est: 241.45M (-62.1%)
|
123.89M
est: 296.20M (-58.2%)
|
334.29M
est.
|
108.46M
est: 351.55M (-69.1%)
|
379.13M
est: 342.47M (+10.7%)
|
179.26M
est: 342.47M (-47.7%)
|
475.73M
est: 393.29M (+21.0%)
|
608.90M
est: 421.52M (+44.5%)
|
440.23M
est: 617.34M (-28.7%)
|
302.49M
est: 464.16M (-34.8%)
|
507.67M
507.67M – 507.67M
+9.4% YoY
|
552.39M
552.39M – 552.39M
+8.8% YoY
|
| EBIT |
102.94M
est: 189.84M (-45.8%)
|
74.76M
est: 207.20M (-63.9%)
|
104.89M
est: 254.18M (-58.7%)
|
286.87M
est.
|
88.56M
est: 301.68M (-70.6%)
|
350.66M
est: 293.88M (+19.3%)
|
158.57M
est: 293.88M (-46.0%)
|
443.54M
est: 337.49M (+31.4%)
|
575.91M
est: 361.72M (+59.2%)
|
406.63M
est: 559.97M (-27.4%)
|
230.65M
est: 421.02M (-45.2%)
|
460.48M
460.48M – 460.48M
+9.4% YoY
|
501.05M
501.05M – 501.05M
+8.8% YoY
|
| Net Income |
85.50M
est: 127.83M (-33.1%)
|
64.66M
est: 63.91M (+1.2%)
|
90.78M
est: 73.04M (+24.3%)
|
83.70M
est.
|
81.22M
est: 88.26M (-8.0%)
|
305.26M
est: 318.05M (-4.0%)
|
147.79M
est: 318.05M (-53.5%)
|
408.08M
est: 402.66M (+1.3%)
|
521.46M
est: 509.03M (+2.4%)
|
362.18M
est: 533.83M (-32.2%)
|
359.84M
est: 503.15M (-28.5%)
|
604.39M
604.39M – 604.39M
+20.1% YoY
|
724.04M
724.04M – 724.04M
+19.8% YoY
|
| SGA |
405.39M
est: 668.43M (-39.4%)
|
501.00M
est: 729.54M (-31.3%)
|
637.84M
est: 894.95M (-28.7%)
|
1.01B
est.
|
667.21M
est: 1.06B (-37.2%)
|
1.13B
est: 1.03B (+9.0%)
|
887.49M
est: 1.03B (-14.2%)
|
1.20B
est: 1.19B (+1.1%)
|
1.51B
est: 1.27B (+18.5%)
|
1.41B
est: 1.86B (-24.2%)
|
1.33B
est: 1.40B (-5.1%)
|
1.53B
1.53B – 1.53B
+9.4% YoY
|
1.67B
1.67B – 1.67B
+8.8% YoY
|
| EPS |
0.56
est: 0.84 (-33.3%)
|
0.42
est: 0.42 (+0.0%)
|
0.59
est: 0.48 (+22.9%)
|
0.55
est.
|
0.53
est: 0.58 (-8.6%)
|
2.01
est: 2.09 (-3.8%)
|
0.96
est: 2.09 (-54.1%)
|
2.68
est: 2.65 (+1.3%)
|
3.41
est: 3.35 (+1.9%)
|
2.38
est: 3.48 (-31.6%)
|
2.35
est: 3.28 (-28.4%)
|
3.94
3.94 – 3.94
+20.1% YoY
|
4.72
4.72 – 4.72
+19.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
221.98M
OE per share TTM
1.44
Owner's Yield
4.76%
Maintenance CapEx ratio
35.73%
Maint CapEx / Avg PPE
14.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 29.6K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 64.0K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 42.1K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 26.6K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
92.4K
Shares Outstanding
153.40M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaoyang Cheng | Financial Director | — | male |
| Fangjing Huang | Supervisor and Director of Legal & Compliance Department | — | female |
| Jie Zhou | Secretary | — | male |
| Jun Wang | President & Director | — | male |
| Xuejun Pei | Vice President | — | male |
| Ying Zhang | Head of Accounting & Accounting Supervisor | — | — |
| Zhijun Huang | Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600976.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
